Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Oncolytics Biotech Inc. (USA)
ONCY | US
1.05
USD0.12
12.90%
ONCY | US
Loading StockChartView...
About Oncolytics Biotech Inc. (USA)
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
13/04/2026
Close
1.05
Open
0.95
High
1.05
Low
0.93
Oncolytics Biotech Inc. a development-stage biopharmaceutical company focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep an intravenously delivered immunotherapeutic agent which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary Canada.
View LessONCY | US
Risk
101.9
Sharpe
0.97
Luna's Score
45/100
Recommendation
Sell
Luna says (ONCY | US)
What's Working
Strength based on increasing price with high volume
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
130.8%1 month
101.9%3 months
107.6%6 months
90.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
7.80
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-1.79
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-36.45M
MarketCap
80.70M
MarketCap(USD)
80.70M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-138.22
Short ratio
5.43
Short perc.
1.41
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.31
Range1M
0.31
Range3M
0.52
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.57
Price X volume
1.41M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.79 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 7.80 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 107.58 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 80.70M | 3.66B | Emerging |
